Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Por Gangadhar, Tara C., Hwu, Wen-Jen, Postow, Michael A., Hamid, Omid, Daud, Adil, Dronca, Roxana, Joseph, Richard, O’Day, Steven J., Hodi, F.S., Pavlick, Anna C., Kluger, Harriet, Oxborough, Romina P., Yang, Aiming, Gazdoiu, Mihaela, Kush, Debra A., Ebbinghaus, Scot, Salama, April K.S.
Publicado no J Immunother (2017)

Five-Year Overall Survival for Patients With Advanced Non‒Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Por Garon, Edward B., Hellmann, Matthew D., Rizvi, Naiyer A., Carcereny, Enric, Leighl, Natasha B., Ahn, Myung-Ju, Eder, Joseph Paul, Balmanoukian, Ani S., Aggarwal, Charu, Horn, Leora, Patnaik, Amita, Gubens, Matthew, Ramalingam, Suresh S., Felip, Enriqueta, Goldman, Jonathan W., Scalzo, Cathie, Jensen, Erin, Kush, Debra A., Hui, Rina
Publicado no J Clin Oncol (2019)